Minimal residual disease in metastatic breast cancer: Treatment with IFN-β, retinoids, and tamoxifen

Francesco Recchia, Luigi Frati, Silvio Rea, Pierfederico Torchio, Gigliola Sica

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The aim of this pilot study was to investigate if chemotherapy (CT) followed by the combination of interferon-β (IFN-β), retinoids, and tamoxifen could be effective in the treatment of metastatic breast cancer (MBC). Thirty-six patients with stage IV carcinoma of the breast were treated with six courses of cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine, and prednisone every 3 weeks (FECPV), followed by two courses of non-cross-resistant drugs, methotrexate, mitomycin C, and mitoxantrone (MMM). Treatment was continued, in responders, with low dose IFN-β, retinyl palmitate, and tamoxifen until relapse of the disease occurred. Among 36 evaluable patients, 23 achieved a clinical response (64%) (95% confidence interval [c.i.] 46%-79%), 7 had stable disease (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in 6, and anemia in 11. Sixteen patients had nausea/vomiting, stomatitis was observed in 9, and diarrhea occurred in 3. Toxicity from maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-107). Median overall survival was 32 months (9-108). Our study shows that this combined approach for the treatment of MBC is feasible, with an acceptable toxicity.

Original languageEnglish
Pages (from-to)41-47
Number of pages7
JournalJournal of Interferon and Cytokine Research
Volume18
Issue number1
Publication statusPublished - Jan 1998

Fingerprint

Retinoids
Residual Neoplasm
Tamoxifen
Interferons
Breast Neoplasms
Mitoxantrone
Epirubicin
Stomatitis
Leukopenia
Mitomycin
Vincristine
Therapeutics
Prednisone
Combination Drug Therapy
Methotrexate
Fluorouracil
Thrombocytopenia
Cyclophosphamide
Nausea
Vomiting

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Minimal residual disease in metastatic breast cancer : Treatment with IFN-β, retinoids, and tamoxifen. / Recchia, Francesco; Frati, Luigi; Rea, Silvio; Torchio, Pierfederico; Sica, Gigliola.

In: Journal of Interferon and Cytokine Research, Vol. 18, No. 1, 01.1998, p. 41-47.

Research output: Contribution to journalArticle

Recchia, Francesco ; Frati, Luigi ; Rea, Silvio ; Torchio, Pierfederico ; Sica, Gigliola. / Minimal residual disease in metastatic breast cancer : Treatment with IFN-β, retinoids, and tamoxifen. In: Journal of Interferon and Cytokine Research. 1998 ; Vol. 18, No. 1. pp. 41-47.
@article{897b23023980471db95bfdd64bc2f559,
title = "Minimal residual disease in metastatic breast cancer: Treatment with IFN-β, retinoids, and tamoxifen",
abstract = "The aim of this pilot study was to investigate if chemotherapy (CT) followed by the combination of interferon-β (IFN-β), retinoids, and tamoxifen could be effective in the treatment of metastatic breast cancer (MBC). Thirty-six patients with stage IV carcinoma of the breast were treated with six courses of cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine, and prednisone every 3 weeks (FECPV), followed by two courses of non-cross-resistant drugs, methotrexate, mitomycin C, and mitoxantrone (MMM). Treatment was continued, in responders, with low dose IFN-β, retinyl palmitate, and tamoxifen until relapse of the disease occurred. Among 36 evaluable patients, 23 achieved a clinical response (64{\%}) (95{\%} confidence interval [c.i.] 46{\%}-79{\%}), 7 had stable disease (19{\%}), and 6 (17{\%}) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in 6, and anemia in 11. Sixteen patients had nausea/vomiting, stomatitis was observed in 9, and diarrhea occurred in 3. Toxicity from maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-107). Median overall survival was 32 months (9-108). Our study shows that this combined approach for the treatment of MBC is feasible, with an acceptable toxicity.",
author = "Francesco Recchia and Luigi Frati and Silvio Rea and Pierfederico Torchio and Gigliola Sica",
year = "1998",
month = "1",
language = "English",
volume = "18",
pages = "41--47",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Minimal residual disease in metastatic breast cancer

T2 - Treatment with IFN-β, retinoids, and tamoxifen

AU - Recchia, Francesco

AU - Frati, Luigi

AU - Rea, Silvio

AU - Torchio, Pierfederico

AU - Sica, Gigliola

PY - 1998/1

Y1 - 1998/1

N2 - The aim of this pilot study was to investigate if chemotherapy (CT) followed by the combination of interferon-β (IFN-β), retinoids, and tamoxifen could be effective in the treatment of metastatic breast cancer (MBC). Thirty-six patients with stage IV carcinoma of the breast were treated with six courses of cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine, and prednisone every 3 weeks (FECPV), followed by two courses of non-cross-resistant drugs, methotrexate, mitomycin C, and mitoxantrone (MMM). Treatment was continued, in responders, with low dose IFN-β, retinyl palmitate, and tamoxifen until relapse of the disease occurred. Among 36 evaluable patients, 23 achieved a clinical response (64%) (95% confidence interval [c.i.] 46%-79%), 7 had stable disease (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in 6, and anemia in 11. Sixteen patients had nausea/vomiting, stomatitis was observed in 9, and diarrhea occurred in 3. Toxicity from maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-107). Median overall survival was 32 months (9-108). Our study shows that this combined approach for the treatment of MBC is feasible, with an acceptable toxicity.

AB - The aim of this pilot study was to investigate if chemotherapy (CT) followed by the combination of interferon-β (IFN-β), retinoids, and tamoxifen could be effective in the treatment of metastatic breast cancer (MBC). Thirty-six patients with stage IV carcinoma of the breast were treated with six courses of cyclophosphamide, 5-fluorouracil, 4-epidoxorubicin, vincristine, and prednisone every 3 weeks (FECPV), followed by two courses of non-cross-resistant drugs, methotrexate, mitomycin C, and mitoxantrone (MMM). Treatment was continued, in responders, with low dose IFN-β, retinyl palmitate, and tamoxifen until relapse of the disease occurred. Among 36 evaluable patients, 23 achieved a clinical response (64%) (95% confidence interval [c.i.] 46%-79%), 7 had stable disease (19%), and 6 (17%) progressed. Leukopenia occurred in 15 patients, thrombocytopenia in 6, and anemia in 11. Sixteen patients had nausea/vomiting, stomatitis was observed in 9, and diarrhea occurred in 3. Toxicity from maintenance therapy was mild and mainly hepatic. Median response duration was 31 months (range 5-107). Median overall survival was 32 months (9-108). Our study shows that this combined approach for the treatment of MBC is feasible, with an acceptable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0031930136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031930136&partnerID=8YFLogxK

M3 - Article

C2 - 9475666

AN - SCOPUS:0031930136

VL - 18

SP - 41

EP - 47

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 1

ER -